Cargando...
Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
Crizotinib, a first-line anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor, has shown promising results for the treatment of locally advanced and metastatic lung cancer presenting the ALK rearrangement. On the other hand, secondary organizing pneumonia (OP) caused by anti-cancer drugs has b...
Guardado en:
| Publicado en: | Case Rep Oncol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
S. Karger AG
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4224257/ https://ncbi.nlm.nih.gov/pubmed/25408663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000366516 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|